Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
DIS$119.48+0.53(+0.45%)137-Room Hilton Garden Inn Lake Buena Vista - Orlando Completes $2.3 Million Renovation8:56:00 AM ETMSFT$556.93+1.13(+0.20%)Voters Just Made Microsoft's Data Centers More Valuable, a Wall Street Veteran Says8:52:56 AM ETJAN$28.91-1.14(-3.79%)BUZZ-Janus Living falls on upsized $748 mln equity raise8:51:45 AM ETBLK$1,240.00+15.63(+1.28%)The London Company Income Equity Vs. Russell 1000 Q3 2026 Commentary8:50:00 AM ETPINS$21.14-0.07(-0.33%)Snap Tumbles 11% as User Growth Miss and Sluggish Ad Sales Overshadow Return to Profit; Pinterest Dips, Meta Holds Steady8:49:25 AM ETGOOG$291.30+4.00(+1.39%)Alphabet: Cheapest Hyperscaler By A Margin8:49:08 AM ETNVDA$197.00-3.29(-1.64%)Nvidia Just Dipped Below $200 for the First Time Since August8:49:06 AM ETMU$755.13-40.33(-5.07%)SanDisk Slides 7%, Micron and Western Digital Fall 5% as Lawmaker's Call for AI Pause Extends Memory Rout8:47:07 AM ETMU$755.13-40.33(-5.07%)How Worried Should Investors Be About Micron Right Now?8:45:37 AM ETVST$116.71-3.59(-2.98%)Vistra Cratered by 25% This Year: One Wall Street Team Says 110% Returns Ahead for Investors8:45:31 AM ETBA$177.39+0.40(+0.23%)Updating The Non-Correlateds: Boeing And IBM Trying To Become Relevant Again8:45:00 AM ETQCOM$152.61-20.58(-11.88%)Qualcomm Sinks 11% as Soft Profit Guidance and Handset Slump Overshadow Beat; Arm Holdings Drops 7%, Skyworks Slides 2%8:43:59 AM ETAMZN$271.15+5.12(+1.92%)Amazon: An Earnings Supercycle Is Taking Shape8:38:41 AM ETNVDA$197.00-3.29(-1.64%)Chinese AI lab Moonshot turned to Europe for Nvidia Blackwell access amid U.S. China curbs, sources tell CNBC8:34:14 AM ETHRL$22.98+0.22(+0.97%)3 Dividend Aristocrats Trading Below Their Historical Valuations8:34:12 AM ETTSM$384.71-10.91(-2.76%)TSMC's AI Opportunity Is Expanding. Here's the Question That Matters for Its Stock Price8:33:37 AM ETHD$359.57+4.13(+1.16%)Three Days, 36 Hands-On Workshop Sessions and HGTV's Biggest Stars: Here's What's Happening Each Day at the First-Ever DIY CON November 6-88:33:00 AM ETMCD$281.60+1.38(+0.49%)McDonald's Q3: 11% EPS Growth And A 50% Operating Margin Say The Sell-Off Was A Mistake8:30:51 AM ETTMO$711.10+4.94(+0.70%)Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance8:30:16 AM ETAAPL$353.66+4.15(+1.19%)Apple Stock Is Up 22%, but 1 Slowing Business Could Test That Valuation8:30:00 AM ETBRK-A$881,000.00+11,699.24(+1.35%)Two in three US-listed companies pay no dividend, a census of SEC filings finds8:30:00 AM ETTEAD$0.20-0.07(-25.93%)Ad platform Teads misses Q3 revenue estimates; suspends guidance8:29:01 AM ETC$126.42+1.65(+1.32%)UPDATE 6-Oil rises as investors weigh uncertainties around Iran war8:27:07 AM ETMCD$281.60+1.38(+0.49%)McDonald's To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Thursday8:22:06 AM ET

CABA · NASDAQ

Cabaletta Bio, Inc.

$1.49 +0.07 (+5.30%)

Company overview

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$253M
Employees
161
Headquarters
Philadelphia, PA
Website
cabalettabio.com
CEO
Steven A. Nichtberger
Listed
October 25, 2019
P/E
-0.76
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$179M
EBITDA
-$172M
Net income
-$175M
EPS
-$1.97
Total assets
$148M
Total debt
$26.5M
Earnings yield
-132.21%

Price chart

1.201.992.783.564.35
CABA 1D NASDAQ O1.50H1.52L1.40C1.42-0.00 (-0.35%)Vol2.86M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CABACabaletta Bio, Inc. Stock news Cabaletta Bio Q3 net loss slightly beats analyst expectations Reuters
CABACabaletta Bio, Inc. Press release Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
CABACabaletta Bio, Inc. Stock news Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
CABACabaletta Bio, Inc. Press release Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
CABACabaletta Bio, Inc. Press release Cabaletta Bio to Participate in Upcoming Investor Conferences GlobeNewswire
CABACabaletta Bio, Inc. Stock news Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns Seeking Alpha
CABACabaletta Bio, Inc. Stock news Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
CABACabaletta Bio, Inc. Press release Cabaletta Bio to Participate in Upcoming Investor Conferences GlobeNewswire
CABACabaletta Bio, Inc. Press release Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
CABACabaletta Bio, Inc. Stock news Kyverna Therapeutics Sinks 13%: Here's Why 24/7 Wall Street
CABACabaletta Bio, Inc. Press release Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress GlobeNewswire
CABACabaletta Bio, Inc. Stock news Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year? Zacks Investment Research
CABACabaletta Bio, Inc. Stock news Cabaletta Bio (CABA) Upgraded to Buy: Here's Why Zacks Investment Research
CABACabaletta Bio, Inc. Stock news Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
CABACabaletta Bio, Inc. Press release Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
CABACabaletta Bio, Inc. Press release Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting GlobeNewswire
CABACabaletta Bio, Inc. Press release Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering GlobeNewswire
CABACabaletta Bio, Inc. Press release Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel GlobeNewswire
CABACabaletta Bio, Inc. Press release Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel Business Wire
CABACabaletta Bio, Inc. Press release Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting GlobeNewswire
See more
FAQ

Questions about Cabaletta Bio, Inc.

What does Cabaletta Bio, Inc. do?
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.
What is CABA's market cap?
Cabaletta Bio, Inc. (CABA) is a listed stock with a live quote. The latest market cap on this page is $253M.
Where is Cabaletta Bio, Inc. headquartered?
Cabaletta Bio, Inc. is headquartered in Philadelphia, PA.
How do I get CABA news from the API?
Call GET /v1/news?tickers=CABA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CABA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CABA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CABA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs